Merck & Co INC (MRK) Shareholder Healthcor Management LP Has Lifted Holding

May 18, 2018 - By Calvin Voll

Merck & Co., Inc. (NYSE:MRK) LogoInvestors sentiment decreased to 0.94 in Q4 2017. Its down 0.12, from 1.06 in 2017Q3. It dived, as 94 investors sold MRK shares while 631 reduced holdings. 123 funds opened positions while 558 raised stakes. 1.93 billion shares or 1.34% less from 1.96 billion shares in 2017Q3 were reported. The California-based Spectrum Asset Mngmt Incorporated (Nb Ca) has invested 0.15% in Merck & Co., Inc. (NYSE:MRK). Azimuth Mngmt Ltd Liability Company reported 232,674 shares or 0.95% of all its holdings. Laurion Capital Mngmt Ltd Partnership invested in 0.19% or 668,981 shares. 34,112 are held by Northeast Invest Management. 20,492 were reported by Mitchell Sinkler And Starr Pa. Ckw Group Inc stated it has 800 shares or 0.01% of all its holdings. Guyasuta Invest Advsr Incorporated stated it has 0.41% of its portfolio in Merck & Co., Inc. (NYSE:MRK). S&Co has 388,165 shares. Beacon Capital Mngmt Inc stated it has 14 shares or 0% of all its holdings. Cap Finance Advisers Limited Liability Company reported 679,700 shares or 0.3% of all its holdings. Drw Secs Ltd Liability invested 0.23% in Merck & Co., Inc. (NYSE:MRK). Cleararc Capital Inc reported 0.48% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Aspen Investment Management Inc accumulated 7,362 shares or 0.29% of the stock. Pekin Singer Strauss Asset Il reported 0.72% in Merck & Co., Inc. (NYSE:MRK). Ftb Inc reported 66,504 shares.

Arthur B Cohen increased its stake in Merck & Co Inc (MRK) by 464.17% based on its latest 2017Q4 regulatory filing with the SEC. Healthcor Management Lp bought 3.21 million shares as the company’s stock declined 4.63% with the market. The hedge fund run by Arthur B Cohen held 3.90 million shares of the health care company at the end of 2017Q4, valued at $219.45 million, up from 691,280 at the end of the previous reported quarter. Healthcor Management Lp who had been investing in Merck & Co Inc for a number of months, seems to be bullish on the $159.28B market cap company. The stock increased 0.23% or $0.14 during the last trading session, reaching $59.21. About 798,058 shares traded. Merck & Co., Inc. (NYSE:MRK) has declined 14.94% since May 18, 2017 and is downtrending. It has underperformed by 26.49% the S&P500.

Healthcor Management Lp, which manages about $3.20B and $3.07 billion US Long portfolio, decreased its stake in Abbvie Inc (NYSE:ABBV) by 236,910 shares to 749,410 shares, valued at $72.48M in 2017Q4, according to the filing. It also reduced its holding in Danaher Corp Del (NYSE:DHR) by 1.13 million shares in the quarter, leaving it with 124,660 shares, and cut its stake in Bioverativ Inc.

More notable recent Merck & Co., Inc. (NYSE:MRK) news were published by: which released: “FDA Lists Brand-Name Drugmakers That Obstruct Generic Development” on May 18, 2018, also with their article: “Morgan Finds Positive Datapoints For MRK and BMY At ASCO” published on May 17, 2018, published: “Dr. Roger Dansey Departure at Merck (MRK) an ‘Incrementally Negative’ – BMO” on May 17, 2018. More interesting news about Merck & Co., Inc. (NYSE:MRK) were released by: and their article: “Merck & Co., Inc. (NYSE:MRK) Trending Upwards” published on May 18, 2018 as well as‘s news article titled: “How Keytruda Saved Merck’s Q1” with publication date: May 01, 2018.

Merck & Co., Inc. (NYSE:MRK) Ratings Coverage

Among 13 analysts covering Merck & Company (NYSE:MRK), 10 have Buy rating, 0 Sell and 3 Hold. Therefore 77% are positive. Merck & Company had 21 analyst reports since November 24, 2017 according to SRatingsIntel. The stock of Merck & Co., Inc. (NYSE:MRK) has “Buy” rating given on Tuesday, April 17 by Guggenheim. The stock of Merck & Co., Inc. (NYSE:MRK) has “Hold” rating given on Monday, February 26 by Jefferies. The company was maintained on Tuesday, February 6 by Leerink Swann. BMO Capital Markets maintained the shares of MRK in report on Wednesday, February 14 with “Outperform” rating. Bank of America maintained the stock with “Buy” rating in Tuesday, November 28 report. The stock of Merck & Co., Inc. (NYSE:MRK) has “Buy” rating given on Monday, April 23 by Goldman Sachs. The rating was upgraded by Leerink Swann to “Buy” on Monday, March 12. The firm earned “Outperform” rating on Monday, February 5 by Credit Suisse. Barclays Capital upgraded the stock to “Overweight” rating in Thursday, April 5 report. Jefferies maintained the shares of MRK in report on Friday, March 23 with “Hold” rating.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: